XML 12 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets - USD ($)
Jun. 30, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 26,437,424 $ 17,164,177
Investment in debt securities - available for sale, at fair value 31,923,285
Accrued interest on investment in debt securities 105,000
Advances and deposits on clinical programs and other current assets 1,844,451 1,660,695
Total current assets 60,310,160 18,824,872
Property and equipment (at cost, less accumulated depreciation and amortization) 458,551 294,551
Other assets:    
Money market investments, restricted cash 6,000,000
Deferred income tax asset 1,845,823
In-process research and development, net 13,366,234 13,366,234
Goodwill 1,976,101 1,976,101
Operating lease right-of-use assets, net 840,195 1,047,336
Other intangible assets, net 113,660
Deposits and other assets 58,761 58,761
Total other assets 22,241,291 18,407,915
Total assets 83,010,002 37,527,338
Current liabilities:    
Accounts payable – trade 2,109,479 2,244,847
Other accrued liabilities 2,312,705 2,458,532
Notes payable – current portion, net of deferred financing costs 1,116,663
Operating lease liability - current portion 458,168 433,413
Deferred revenue - current portion 500,000 500,000
Total current liabilities 5,380,352 6,753,455
Earn-out milestone liability 7,088,000 7,018,000
Notes payable – non-current portion, net of deferred financing costs 5,763,087 3,934,497
Operating lease liability - non-current portion 475,051 710,305
Deferred revenue - non-current portion 250,000 500,000
Total liabilities 18,956,490 18,916,257
Commitments and contingencies
Stockholders’ equity:    
Preferred Stock - $0.01 par value (100,000 shares authorized, and no shares issued or outstanding at June 30, 2021 and December 31, 2020)
Common stock - $0.01 par value (112,500,000 shares authorized; 86,558,070 and 40,701,356 shares issued at June 30, 2021 and December 31, 2020, respectively, and 86,557,736 and 40,701,022 shares outstanding at June 30, 2021 and December 31, 2020, respectively) 865,581 407,014
Additional paid-in capital 386,414,630 330,289,596
Accumulated other comprehensive loss (3,770)
Accumulated deficit (323,137,741) (312,000,341)
Total stockholders’ equity before treasury stock 64,138,700 18,696,269
Treasury stock, at cost (334 shares at June 30, 2021 and December 31, 2020) (85,188) (85,188)
Total stockholders’ equity 64,053,512 18,611,081
Total liabilities and stockholders’ equity $ 83,010,002 $ 37,527,338